Circulating suPAR in two cohorts of primary FSGS

Journal of the American Society of Nephrology

Volumn 23, Issue 12, 2012, Pages 2051-2059

  Wei, Changli ^a   Trachtman, Howard ^b   Li, Jing ^a   Dong, Chuanhui ^a   Friedman, Aaron L ^c   Gassman, Jennifer J ^d   McMahan, June L ^d   Radeva, Milena ^d   Heil, Karsten M ^e   Trautmann, Agnes ^e   Anarat, Ali ^f   Emre, Sevinc ^g   Ghiggeri, Gian M ^h   Ozaltin, Fatih ⁱ   Haffner, Dieter ^j   Gipson, Debbie S ^k   Kaskel, Frederick ^l   Fischer, Dagmar Christiane ^m   Schaefer, Franz ^e   Reiser, Jochen ⁿ  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^g ISTANBUL UNIVERSITY   (Turkey)

^h G GASLINI INSTITUTE   (Italy)

ⁱ HACETTEPE UNIVERSITY   (Turkey)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^l ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^m ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

ⁿ RUSH UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PODOCIN; SOLUBLE UROKINASE RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ARTICLE; CHILD; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; REMISSION;

EID: 84870546490     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012030302     Document Type: Article

References (30)

1. Benchimol C: Focal segmental glomerulosclerosis: Pathogenesis and treatment. Curr Opin Pediatr 15: 171-180, 2003
2. Korbet SM: Treatment of primary focal segmental glomerulosclerosis. Kidney Int 62: 2301-2310, 2002
3. Boyer O, Moulder JK, Somers MJ: Focal and segmental glomerulosclerosis in children: A longitudinal assessment. Pediatr Nephrol 22: 1159-1166, 2007
4. Barisoni L, Schnaper HW, Kopp JB: Advances in the biology and genetics of the podocytopathies: Implications for diagnosis and therapy. Arch Pathol Lab Med 133: 201-216, 2009
5. Santín S, Bullich G, Tazón-Vega B, García-Maset R, Giménez I, Silva I, Ruíz P, Ballarín J, Torra R, Ars E: Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 6: 1139-1148, 2011
6. McCarthy ET, Sharma M, Savin VJ: Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5: 2115-2121, 2010
7. Cattran D, Neogi T, Sharma R, McCarthy ET, Savin VJ: Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 14: 448-453, 2003 (Pubitemid 36150869)
8. McCarthy ET, Sharma M, Sharma R, Falk RJ, Jennette JC: Sera from patients with collapsing focal segmental glomerulosclerosis increase albumin permeability of isolated glomeruli. J Lab Clin Med 143: 225-229, 2004 (Pubitemid 38510118)
9. Savin VJ, Sharma M: Plasma "factors" in recurrent nephrotic syndrome after kidney transplantation: Causes or consequences of glomerular injury? Am J Kidney Dis 54: 406-409, 2009
10. Reiser J, Wei C, Tumlin J: Soluble urokinase receptor and focal segmental glomerulosclerosis. Curr Opin Nephrol Hypertens 21: 428-432, 2012
11. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952-960, 2011
12. Gao W, Wang Z, Bai X, Xi X, Ruan C: Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients. Thromb Res 102: 25-31, 2001 (Pubitemid 32367907)
13. Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F: Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 15: R63, 2011
14. Yilmaz G, Köksal I, Karahan SC, Mentese A: The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome. Clin Biochem 44: 1227-1230, 2011
15. Gipson DS, Trachtman H, Kaskel FJ, Radeva MK, Gassman J, Greene TH, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Middleton JP, Vehaskari VM, Hogan SL, Vento S, Flynn PA, Powell LM, McMahan JL, Siegel N, Friedman AL: Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney Int 79: 678-685, 2011
16. Lyngbæk S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, Andersen O, Linneberg A, Madsbad S, Haugaard SB, Eugen-Olsen J, Jeppesen J: CRP and suPAR are differently related to anthropometry and subclinical organ damage [published online ahead of print March 27, 2012]. Int J Cardiol doi:10.1016/j.ijcard.2012. 03.040
17. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011
18. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group: Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J Am Soc Nephrol 16: 1061-1068, 2005 (Pubitemid 41710316)
19. Burgess E: Management of focal segmental glomerulosclerosis: Evidence- based recommendations. Kidney Int Suppl 70: S26-S32, 1999
20. Ponticelli C, Passerini P: Other immunosuppressive agents for focal segmental glomerulosclerosis. Semin Nephrol 23: 242-248, 2003 (Pubitemid 36397107)
21. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P: The actin cytoskeleton of kidney podocytes is a direct target of the anti-proteinuric effect of cyclosporine A. Nat Med 14: 931-938, 2008
22. Billing H, Müller D, Ruf R, Lichtenberger A, Hildebrandt F, August C, Querfeld U, Haffner D: NPHS2 mutation associated with recurrence of proteinuria after transplantation. Pediatr Nephrol 19: 561-564, 2004 (Pubitemid 38594300)
23. Caridi G, Bertelli R, Carrea A, DiDuca M, Catarsi P, Artero M, Carraro M, Zennaro C, Candiano G, Musante L, Seri M, Ginevri F, Perfumo F, Ghiggeri GM: Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol 12: 2742-2746, 2001 (Pubitemid 33115421)
24. Carraro M, Caridi G, Bruschi M, Artero M, Bertelli R, Zennaro C, Musante L, Candiano G, Perfumo F, Ghiggeri GM: Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol 13: 1946-1952, 2002 (Pubitemid 34700621)
25. Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M: Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 151: 288-292, 2008
26. Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, Savin V, Somers M, Pinsk M, Greene T: Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: Study design. BMC Nephrol 12: 8, 2011
27. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMahan JL, Siegel N, D'Agati VD, Friedman AL: Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 80: 868-878, 2011
28. Anuurad E, Tracy RP, Pearson TA, Beckett L, Berglund L: Comparison of C-reactive protein and metabolic syndrome as cardiovascular risk factors in African-Americans and European-Americans. Am J Cardiol 103: 523-527, 2009
29. Wigger M, Schaible J, Muscheites J, Kundt G, Haffner D, Fischer DC: Fetuin-A serum concentrations in healthy children. Ann Clin Biochem 46: 511-513, 2009
30. Fischer DC, Mischek A, Wolf S, Rahn A, Salweski B, Kundt G, Haffner D: Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase [published online ahead of print September 14, 2012]. Ann Clin Biochem doi:10.1258/acb.2012.011274